Alpha Cognition Inc. (ACOGF) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Vancouver, BC, 加拿大. 現任CEO為 Michael E. McFadden.
ACOGF 擁有 IPO日期為 2021-06-28, 在 Other OTC, 市值為 $35.66M.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
